StockData
Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc. (FULC) stock

FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$3.75+0.04 (+1.08%)

Close on Nov 17, 2026Market cap $286.11MP/E –Yield –

Earnings

Fulcrum Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q1 FY2026
–
EPS, Q1 FY2026
-$0.25
Latest guidance
Issued
Nov 13, 2024 · 2 items

Quarterly results

Revenue and earnings per share from each of Fulcrum Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q1 FY2026ended Mar 31, 2026Apr 27, 2026before the open––-$0.25Release
Q4 FY2025ended Dec 31, 2025Feb 24, 2026before the open––-$0.31Release
Q3 FY2025ended Sep 30, 2025Oct 29, 2025before the open––-$0.31Release
Q2 FY2025ended Jun 30, 2025Jul 29, 2025before the open––-$0.28Release
Q1 FY2025ended Mar 31, 2025May 1, 2025before the open–––Release
Q4 FY2024ended Dec 31, 2024Feb 25, 2025before the open––-$0.31Release
Q3 FY2024ended Sep 30, 2024Nov 13, 2024before the open$0-100.0%-$0.35Release
Q2 FY2024ended Jun 30, 2024Jul 31, 2024before the open$80.00M+8788.9%–Release
Q1 FY2024ended Mar 31, 2024May 13, 2024before the open$0-100.0%-$0.43Release
Q4 FY2023ended Dec 31, 2023Feb 27, 2024before the open$900.00K+28.6%-$0.40Release
Q3 FY2023ended Sep 30, 2023Nov 7, 2023before the open$800.00K-33.3%-$0.39Release
Q2 FY2023ended Jun 30, 2023Aug 3, 2023before the open$900.00K-52.6%-$0.38Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Fulcrum Therapeutics guided for has been reported

Guidance history

Every forecast Fulcrum Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 13, 2024cash burnFY2025$55.00M – $65.00MNew
Nov 13, 2024cash, cash equivalents, and marketable securitiesFY2024$240.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Fulcrum Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Update
  3. News
  4. Results
  5. Results
  6. Results
  7. News
  8. Update
  9. Update
  10. Results
  11. Update
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?